EUVIMEDEUVIMED entdecken
Crossref

Pitfalls of using polymerase chain reaction–based assays for JAK2 and CALR exon 9 variant testing in myeloproliferative neoplasms: Knowing when to go the extra mile!

Kritika Krishnamurthy iD, Jiani Chai, Yanhua Wang iD, Rizwan Naeem, D Yitzchak Goldstein iD

American Journal of Clinical Pathology · 2024

DOI: 10.1093/ajcp/aqad122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2024. Verfasst von Kritika Krishnamurthy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Montefiore Medical Center, Bronx, NY, US. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The BCR::ABL1 negative myeloproliferative neoplasms are sequentially tested for JAK2 p.V617F, followed by CALR exon 9 pathogenic variants. Historically, these variants were thought to be mutually exclusive. However, recent reports indicate coexisting JAK2 p.V617F and CALR exon 9 somatic variants.

Methods

Analysis of JAK2 p.V617F and CALR exon 9 variant was performed by polymerase chain reaction (PCR)–based assays. Subsequent testing was performed on the Genexus integrated sequencer (ThermoFisher) using the Oncomine myeloid assay GX v2.

Results

CALR exon 9 variants were positive in 3 cases, while 2 were positive for JAK2 p.V617F on PCR-based assays. Next-generation sequencing confirmed the JAK2 P.V617F status in all cases. CALR variants resulting in in-frame deletions were identified in 2 cases at a variant allele frequency of 52.16% and 50.91%, while the third case had an intronic CALR variant c.-48G>A at a variant allele frequency of 51.1%. Thus, CALR variants in all 3 cases were interpreted as potentially germline. Of the 228 cases that underwent JAK2 p.V617F and CALR cotesting in the past 2 years, only these 2 cases were positive for both JAK2 p.V617F and CALR exon 9 variants.

Conclusions

These cases highlight the importance of understanding the pitfalls of molecular techniques in current practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloproliferative DisordersNeoplasmsHumansCalreticulinMutationExonsJanus Kinase 2Polymerase Chain Reaction

Stichwörter der Autor:innen

CALR exon 9 variantsJAK2 V617FPCR-based testinggermline vs somaticmyeloproliferative neoplasm

Substanzen

CalreticulinJanus Kinase 2JAK2 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Montefiore Medical Center, Bronx, NY, US.
  • Albert Einstein College of Medicine, Bronx, NY, US.

ORCID-Profile: Kritika Krishnamurthy, Yanhua Wang, D Yitzchak Goldstein

Zitieren

APA

Krishnamurthy, K., Chai, J., Wang, Y., Naeem, R., & Goldstein, D. Y. (2024). Pitfalls of using polymerase chain reaction–based assays for JAK2 and CALR exon 9 variant testing in myeloproliferative neoplasms: Knowing when to go the extra mile!. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqad122

Vancouver

Krishnamurthy K, Chai J, Wang Y, Naeem R, Goldstein DY. Pitfalls of using polymerase chain reaction–based assays for JAK2 and CALR exon 9 variant testing in myeloproliferative neoplasms: Knowing when to go the extra mile!. American Journal of Clinical Pathology. 2024. doi:10.1093/ajcp/aqad122

BibTeX
@article{Krishnamurthy2024,
  author = {Krishnamurthy, Kritika and Chai, Jiani and Wang, Yanhua and Naeem, Rizwan and Goldstein, D Yitzchak},
  title = {Pitfalls of using polymerase chain reaction–based assays for JAK2 and CALR exon 9 variant testing in myeloproliferative neoplasms: Knowing when to go the extra mile!},
  journal = {American Journal of Clinical Pathology},
  year = {2024},
  doi = {10.1093/ajcp/aqad122}
}
Kostenlos starten →